Yuji Suzuki
CEO
bitBiome
bitBiome utilizes single-cell sequencing technology to catalog and evolve microbial genomes, creating a diverse database of over 2 billion sequences. This platform addresses the need for unique enzymes and proteins to enhance biomanufacturing processes across various industries, including drug production and sustainable materials development.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many industries, including drug production and sustainable materials development, require unique enzymes and proteins to enhance biomanufacturing processes. Existing methods for discovering and cataloging microbial genomes are inefficient, limiting the availability of diverse biological tools.
Solution
bitBiome utilizes a single-cell sequencing platform to efficiently catalog and evolve microbial genomes, creating a large database of diverse sequences. Their technology addresses the need for novel enzymes and proteins by offering a more efficient method for identifying and developing these biological tools. The platform leverages bioinformatics and AI-driven enzyme engineering to improve accuracy while reducing the time and cost associated with traditional methods. This enables the discovery of unique enzymes and proteins that can be applied across various industries to enhance biomanufacturing processes.
Target Audience
The primary customers are companies in drug biomanufacturing, materials science, and textiles that require novel enzymes and proteins to improve their manufacturing processes.
Features
- bit-MAP®: Single-cell sequencing technology for microbes, claimed to be 100x more efficient than conventional methods.
- bit-GEM: A database of over 2 billion sequences, built on single-cell sequencing of microbes from natural samples.
- bit-QED: Bioinformatics and AI-driven enzyme engineering for improvements in accuracy at decreased time and cost.